Gastric stimulation to treat the type 2 diabetes: results on week 16
Abstract
Background/Aim. Gastric contraction modulation (GCM) with the implanted DIAMOND device improves glycemic control and decreases weight. The main aim of this study was to evaluate the early efficacy of GCM using the DIAMOND (previously named TANTALUS) System in the improvement of glycemic control measured by changes in glycosylated hemoglobin (HbA1c). The effects of GCM on weight loss, body mass index (BMI), reduction of the waist circumference and metabolic parameters other than HbA1c were also evaluated. Methods. A total of 18 adult patients with type 2 diabetes were surgically treated at the Department for Minimally Invasive Upper Digestive Surgery, Clinic for Digestive Surgery in Belgrade, Serbia, using gastric pacemaker (DIAMOND System) from November 2014 to March 2016. Out of the total number of patients, 11 finished week 16 visit and were enroled in this prospective cohort study. Results. During the observed period, the average weight loss amounted to 8.05 kg (p < 0.05). The average difference between the baseline fasting glucose level and the level after 16 weeks period is 2.56 mmol/L. Similar findings were noted in fasting insulin levels, with an average decrease of 6.44 m/U/L after 16 weeks. The majority of patients experienced a decrease in HbA1c value: in 4 patients higher than 2%, and in 4 patients up to 2% (p < 0.05). Lower level of fasting insulin with simultaneous decrease in fasting glucose indicates improvement in insulin sensitivity on week 16 [homeostatic model assessment of insulin resistance (HOMA IR) average 5.25]. Conclusion. Gastric stimulation using the DIAMOND System for 16 weeks causes significant early improvement in glycemic control and insulin resistance. There is an additional positive effect on weight loss, body mass index (BMI) and reduction of the waist circumference as a main parameter of the metabolic syndrome.
References
References
World Health Organization.Global status report on noncommu-nicable diseases. Geneva: World Health Organization; 2014.
Department of Health and Human Services, Centers for Dis-ease Control and Prevention, National Center for Health Sta-tistics. Atlanta, Health United States, with chartbook on trends of in the health of Americans; 2003.
Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hyper-tension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003; 237(6): 751−6; discussion 757−8.
Dixon JB, O’Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 2002; 25(2): 358−63.
Bohdjalian A, Prager G, Rosak C, Weiner R, Jung R, Schramm M, et al. Improvement in glycemic control in morbidly obese type 2 diabetic subjects by gastric stimulation. Obes Surg 2009; 19(9): 1221–7.
Sanmiguel CP, Conklin JL, Cunneen SA, Barnett P, Phillips EH, Kipnes M, et al. Gastric electrical stimulation with the TAN-TALUS System in obese type 2 diabetes patients: Effect on weight and glycemic control. J Diabetes Sci Technol 2009; 3(4): 964−70.
Lebovitz HE, Ludvik B, Yaniv I, Haddad W, Schwartz T, Aviv R. Metacure Investigator Group. Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm. Diabet Med 2013; 30(6): 687−93.
American Diabetes Association. (6) Glycemic targets. Diabetes Care 2015; 38 Suppl: S33−40.
Handgraaf HJ, Nelissen RM, Bianchi R, Meesters B, Greve JW. A gastric pacemaker in obese type 2 diabetic patients. Ned Tijdschr Geneeskd 2013; 157(0): A5929. (Dutch)
Bugajski AJ, Gil K, Ziomber A, Zurowski D, Zaraska W, Thor PJ. Effect of long-term vagal stimulation on food intake and body weight during diet induced obesity in rats. J Physiol Pharmacol 2007; 58 Suppl 1: 5−12.
Konturek PC, Konturek JW, Cześnikiewicz-Guzik M, Brzozowski T, Sito E, Konturek SJ. Neuro-hormonal control of food intake: basic mechanisms and clinical implications. J Physiol Pharmacol. 2005; 56 Suppl 6: 5−25.
Konturek SJ, Konturek JW, Pawlik T, Brzozowski T. Brain-gut axis and its role in the control of food intake. J Physiol Pharmacol 2004; 55(1 Pt 2): 137−54.
Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin and ghrelin before and after weight loss induced by gastric bypass surgery in morbidity obese subjects. J Clin Endocrinol Metab 2003; 88(4): 1594−602.
Dobak JD. Dynamic nerve stimulation for treatment of disor-ders. United States Patent and Trademark Office 2005. p. 37.
Gil K, Bugajski A, Thor P. Electrical vagus nerve stimulation decreases food consumption and weight gain in rats fed a high-fat diet. J Physiol Pharmacol 2011; 62(6): 637−46.
Bohdjalian A, Prager G, Aviv R, Policker S, Schindler K, Kretschmer S, et al. One-year experience with Tantalus: A new surgical ap-proach to treat morbid obesity. Obes Surg 2006; 16(5): 627−34.
Bertoli S, Leone A, Vignati L, Spadafranca A, Bedogni G, Vanzulli A, et al. Metabolic correlates of subcutaneous and visceral ab-dominal fat measured by ultrasonography: a comparison with waist circumference. Nutr J 2016; 15: 2.
Bohdjalian A, Ludvik B, Guerci B, Bresler L, Renard E, Nocca D, et al. Improvement in glycemic control by gastric electrical stimulation (TANTALUS) in overweight subjects with type 2 diabetes. Surg Endosc 2009; 23(9): 1955−60.
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273(5 Pt 1): E981−8.
Drucker DJ, Nauck MA. The incretin system: Glucagon-like-peptie-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368(9548): 1696−705.